IO Frontiers World 2019

Regulatory Opportunities and Commercialising CAR-T

With Peter Olagunju, Bluebird Bio

So much has happened in the immuno-oncology industry since we spoke to Peter at last year’s IO Frontiers World in Miami. However, the balance between opportunities and challenges remain and we still need discussion and collaboration to

With every new regulatory opportunity come great challenges…

Peter Olagunju is the Senior Technical Director at Bluebird Bio and has a wealth of CMC and supply chain experience across a range of advanced therapies. In this video, Peter gives insight into:

  • The opportunities brought by accelerated clinical development
  • Tension points in CMC as a result of expedited time frames
  • Improving the shelf life of autologous therapy starting materials

 

These discussions will continue at IO Frontiers World this January 22-25 in Miami; the most senior partnering event for the immuno-oncology industry. Find out more about the meeting here or go straight to the agenda.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy